• Mashup Score: 3
    Illumina responds to European Commission's divestiture order - 7 month(s) ago

    SAN DIEGO, Oct. 13, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ:ILMN), has received an order from the European Commission (EC) directing the company to divest GRAIL. Receipt of the order is an important next step in evaluating divestiture options for GRAIL. Illumina is committed to resolving all issues regarding GRAIL in a timely manner, with the objective of achieving the maximum value for shareholders and the best outcome for GRAIL. Notably, the terms of the order provide for flexibility in transaction

    Source: www.illumina.com
    Categories: Healthcare Professionals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of matthewherper
      matthewherper

      $ILMN recognizes it has at most 15 months to figure out what to do w/ Grail, but reiterates it does not believe EU has any jurisdiction. https://t.co/mYvoNFw38R

  • Mashup Score: 0
    Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer - 8 month(s) ago

    SAN DIEGO, Sept. 5, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has appointed Jacob Thaysen, Ph.D., senior vice president of Agilent Technologies and president of its Life Sciences and Applied Markets Group, as Chief Executive Officer, effective September 25, 2023. Mr. Thaysen’s extensive background and experience in genomics, life sciences, and technology fits closely with Illumina’s

    Source: www.illumina.com
    Categories: Healthcare Professionals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of matthewherper
      matthewherper

      $ilmn appoints Jacob Thaysen of Agilent as its new CEO. Two things: (1) He’s not Francis deSouza (2) He’s also not Jay Flatley, who many people hoped would come back. https://t.co/x7Rhaydi0N

  • Mashup Score: 3
    Press Release - 10 month(s) ago

    Alliance aims to accelerate therapeutic development and expand the diversity of genomic data through inclusion of more samples from currently underrepresented ancestries , /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company…

    Source: www.illumina.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of PhilFebboMD_CMO
      PhilFebboMD_CMO

      What do you get when you combine 250,000 WGS with 20 years of structured clinical data? You get The Alliance for Genomic Discovery with partners including @abbvie, @AstraZeneca, @Bayer, @Merck, @NashvilleBio, and @illumina. Welcome to the #genome era! https://t.co/8p9NtYrEod

  • Mashup Score: 0
    Addressing the genomics education gap - 11 month(s) ago

    With limited space in the curricula for genomics, residents and physicians are turning to other sources for training

    Source: www.illumina.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of PhilFebboMD_CMO
      PhilFebboMD_CMO

      I'm thrilled about this app on @XPeer5 that is helping address the #genomics education gap! Kudos to my peers Holly Snyder and Maria Martinez-Fresno for their efforts on this much needed resource. https://t.co/EvVPgzSam9 #MedGeneEd23

  • Mashup Score: 4
    Press Release - 12 month(s) ago

    , /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today recognized the progress and impact of genomic technologies on pathogen preparedness and response. Following the boost in sequencing infrastructure and capabilities driven by the COVID-19 pandemic, today genomic technologies are enabling public health agencies and health care…

    Source: www.illumina.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of PhilFebboMD_CMO
      PhilFebboMD_CMO

      Dengue & Marburg & SARS, Oh My! As COVID-19 becomes an endemic public health challenge, genomic surveillance will serve as a critical component of a comprehensive global pandemic early warning system. A few thoughts about recent past, present, and future. https://t.co/J9abS4p76U

  • Mashup Score: 0
    Press Release - 1 year(s) ago

    , /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today filed its preliminary proxy statement with the Securities and Exchange Commission, which contains important information for shareholders. The activist investor Carl Icahn has nominated three of his associates to stand for election to the Board of Directors at Illumina’s 2023 Annual…

    Source: www.illumina.com
    Categories: Healthcare Professionals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of matthewherper
      matthewherper

      Illumina files its proxy, tells investors to vote against Icahn nominees. https://t.co/y8CX8Z0prn

  • Mashup Score: 1
    A new genomic atlas could help save endangered elephants - 1 year(s) ago

    Data from this international partnership will assist biologists in protecting the herds they study

    Source: www.illumina.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of PhilFebboMD_CMO
      PhilFebboMD_CMO

      Now that is a big genome! Great to see genomics working to maintain biodiversity - a critical element to the health of the world. While actually only 30% bigger than the human genome, this new genomic atlas that could help save wild African #elephants. 🐘 https://t.co/d1M5UC0p4D https://t.co/jgelqusHR2

Load More